<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02307071</url>
  </required_header>
  <id_info>
    <org_study_id>OTSCM</org_study_id>
    <nct_id>NCT02307071</nct_id>
  </id_info>
  <brief_title>Occipital Transcutaneous Stimulation in Chronic Migraine</brief_title>
  <acronym>OSCRO</acronym>
  <official_title>Transcutaneous Suboccipital Neurostimulation for the Treatment of Chronic Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of Liege</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect in chronic migraine patients of daily 20
      minute-transcutaneous sub occipital neurostimulation using the occipital Cefaly° device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic migraine is a disabling neurological condition affecting 0.5-2% of the population.

      CM is difficult to treat and preventive treatment options are limited. Due to the
      inefficiency of available and the lack of new preventive anti-migraine drug, neurostimulation
      methods have raised great interest in recent years.

      The ONSTIM study showed a reduction in headache frequency in 39% of patients treated with
      active ONS during 12 weeks, compared to no improvement in the &quot;non-effectively&quot; stimulated or
      medically treated groups.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Monthly frequency of migraine days</measure>
    <time_frame>2 months treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monthly frequency of headache days</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monthly frequency of total headache days</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative monthly headache hours</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monthly acute drug intake</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Migraine</condition>
  <arm_group>
    <arm_group_label>Cefaly Kit Arnold</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Occipital transcranial stimulation is implemented in occipital region at 16 mA of intensity, for 20 minutes, everyday for 3 months, in 20 chronic migraine patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cefaly Kit Arnold</intervention_name>
    <description>Occipital neurostimulation can have a therapeutic effect in chronic migraine treatment, thus representing a possible therapeutic option in patients that do not respond to any medication.</description>
    <arm_group_label>Cefaly Kit Arnold</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of chronic migraine (ICHD III beta 1.3) with or without medication overuse

        Exclusion Criteria:

          -  other diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Schoenen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Liège</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Delphine Magis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Liège</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Cosseddu, MD</last_name>
    <phone>+3242256925</phone>
    <email>cossedduanna@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHR Citadelle</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Cosseddu, MD</last_name>
      <phone>+3242256925</phone>
      <email>cossedduanna@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Delphine Magis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Schoenen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2014</study_first_submitted>
  <study_first_submitted_qc>December 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2014</study_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Liege</investigator_affiliation>
    <investigator_full_name>Jean Schoenen</investigator_full_name>
    <investigator_title>Honorary Full Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

